公开(公告)号：US20150266881A1

公开(公告)日：2015-09-24

申请号：US14435085

申请日：2013-10-11

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Naoki Tomita ,  Daisuke Tomita ,  Yusuke Tominari ,  Shinichi Imamura ,  Shinji Morimoto ,  Takuto Kojima ,  Masashi Toyofuku ,  Yasushi Hattori ,  Tomohiro Kaku ,  Mitsuhiro Ito

IPC: C07D487/04 ,  C07D231/38 ,  C07C237/38 ,  C07C237/30 ,  C07D241/12 ,  C07D213/36 ,  C07D471/04 ,  C07D207/46 ,  C07D241/18 ,  C07D319/18 ,  C07D265/36 ,  C07D333/20 ,  C07D285/135 ,  C07D277/38 ,  C07D405/12 ,  C07D417/12 ,  C07D413/12 ,  C07D223/12 ,  C07D513/04 ,  C07C237/40

CPC classification number: C07D487/04 ,  A61K45/06 ,  C07C237/30 ,  C07C237/38 ,  C07C237/40 ,  C07C255/29 ,  C07C255/58 ,  C07C255/60 ,  C07C317/40 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07D207/12 ,  C07D207/46 ,  C07D211/58 ,  C07D213/36 ,  C07D213/40 ,  C07D223/12 ,  C07D231/38 ,  C07D231/40 ,  C07D241/12 ,  C07D241/18 ,  C07D261/14 ,  C07D265/36 ,  C07D277/38 ,  C07D285/135 ,  C07D295/135 ,  C07D309/14 ,  C07D319/18 ,  C07D333/20 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D513/04

Abstract: The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R1, R2 and R3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R2 and R3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.

Abstract translation: 本发明提供了具有赖氨酸特异性脱甲基酶1抑制作用的化合物，可用作精神分裂症，阿尔茨海默病，帕金森病或亨廷顿病等预防或治疗药物等药物。 本发明涉及由下式表示的化合物：其中A是任选具有取代基的烃基或任选具有取代基的杂环基; B是任选具有其它取代基的苯环; R 1，R 2和R 3各自独立地为氢原子，任选具有取代基的烃基或任选具有取代基的杂环基; A和R1任选地彼此键合，与相邻的氮原子一起形成任选具有取代基的环状基团; R 2和R 3可以相互键合，与相邻的氮原子一起形成任选具有取代基的环状基团或其盐。

公开(公告)号：US09751885B2

公开(公告)日：2017-09-05

申请号：US14435085

申请日：2013-10-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Naoki Tomita ,  Daisuke Tomita ,  Yusuke Tominari ,  Shinichi Imamura ,  Shinji Morimoto ,  Takuto Kojima ,  Masashi Toyofuku ,  Yasushi Hattori ,  Tomohiro Kaku ,  Mitsuhiro Ito

IPC: C07D487/04 ,  C07C255/58 ,  C07C255/60 ,  C07D231/40 ,  C07C317/40 ,  C07C237/30 ,  C07C237/38 ,  C07C237/40 ,  C07C255/29 ,  A61K45/06 ,  C07D309/14 ,  C07D319/18 ,  C07D413/12 ,  C07D241/12 ,  C07D417/12 ,  C07D261/14 ,  C07D207/12 ,  C07D285/135 ,  C07D211/58 ,  C07D295/135 ,  C07D213/40 ,  C07D207/46 ,  C07D213/36 ,  C07D223/12 ,  C07D231/38 ,  C07D241/18 ,  C07D265/36 ,  C07D277/38 ,  C07D333/20 ,  C07D405/12 ,  C07D471/04 ,  C07D513/04

CPC classification number: C07D487/04 ,  A61K45/06 ,  C07C237/30 ,  C07C237/38 ,  C07C237/40 ,  C07C255/29 ,  C07C255/58 ,  C07C255/60 ,  C07C317/40 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07D207/12 ,  C07D207/46 ,  C07D211/58 ,  C07D213/36 ,  C07D213/40 ,  C07D223/12 ,  C07D231/38 ,  C07D231/40 ,  C07D241/12 ,  C07D241/18 ,  C07D261/14 ,  C07D265/36 ,  C07D277/38 ,  C07D285/135 ,  C07D295/135 ,  C07D309/14 ,  C07D319/18 ,  C07D333/20 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D513/04

Abstract: The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R1, R2 and R3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R2 and R3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.

公开(公告)号：US09682925B2

公开(公告)日：2017-06-20

申请号：US15005574

申请日：2016-01-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Naoki Tomita ,  Shigeo Kajii ,  Douglas Robert Cary ,  Daisuke Tomita ,  Shinichi Imamura ,  Ken Tsuchida ,  Satoru Matsuda ,  Ryujiro Hara

IPC: A61K31/167 ,  A61K31/36 ,  A61K31/366 ,  A61K31/40 ,  A61K31/402 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/428 ,  A61K31/429 ,  A61K31/433 ,  A61K31/451 ,  A61K31/495 ,  A61K31/55 ,  C07C233/80 ,  A61K31/381 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4453 ,  A61K31/4468 ,  C07D309/14 ,  C07C271/22 ,  C07D317/58 ,  C07D223/16 ,  C07D231/14 ,  C07D231/20 ,  C07D231/22 ,  C07D333/20 ,  C07D231/56 ,  C07D233/61 ,  C07D233/64 ,  C07D405/04 ,  C07D239/36 ,  C07D409/04 ,  C07D471/04 ,  C07D261/08 ,  C07D261/10 ,  C07D263/32 ,  C07D263/34 ,  C07C235/56 ,  C07D207/06 ,  C07C237/40 ,  C07D495/04 ,  C07D207/337 ,  C07D277/20 ,  C07D277/28 ,  C07D277/30 ,  C07D209/08 ,  C07D277/62 ,  C07D209/42 ,  C07D513/04 ,  C07D209/46 ,  C07D209/48 ,  C07D285/06 ,  C07D211/56 ,  C07D211/58 ,  C07D295/14 ,  C07D211/76 ,  C07D213/04 ,  C07D213/38 ,  C07D213/56 ,  C07D211/98 ,  C07D335/02 ,  C07C237/42 ,  C07C271/20 ,  C07D211/40 ,  C07D231/26 ,  C07D295/135 ,  C07D295/155

CPC classification number: C07C233/80 ,  A61K31/167 ,  A61K31/36 ,  A61K31/366 ,  A61K31/381 ,  A61K31/40 ,  A61K31/402 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/428 ,  A61K31/429 ,  A61K31/433 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4453 ,  A61K31/4468 ,  A61K31/451 ,  A61K31/495 ,  A61K31/55 ,  C07C235/56 ,  C07C237/40 ,  C07C237/42 ,  C07C271/20 ,  C07C271/22 ,  C07C2601/02 ,  C07C2601/18 ,  C07C2602/08 ,  C07D207/06 ,  C07D207/337 ,  C07D209/08 ,  C07D209/42 ,  C07D209/46 ,  C07D209/48 ,  C07D211/40 ,  C07D211/56 ,  C07D211/58 ,  C07D211/76 ,  C07D211/98 ,  C07D213/04 ,  C07D213/38 ,  C07D213/56 ,  C07D223/16 ,  C07D231/14 ,  C07D231/20 ,  C07D231/22 ,  C07D231/26 ,  C07D231/56 ,  C07D233/61 ,  C07D233/64 ,  C07D239/36 ,  C07D261/08 ,  C07D261/10 ,  C07D263/32 ,  C07D263/34 ,  C07D277/20 ,  C07D277/28 ,  C07D277/30 ,  C07D277/62 ,  C07D285/06 ,  C07D295/135 ,  C07D295/14 ,  C07D295/155 ,  C07D309/14 ,  C07D317/58 ,  C07D333/20 ,  C07D335/02 ,  C07D405/04 ,  C07D409/04 ,  C07D471/04 ,  C07D495/04 ,  C07D513/04

Abstract: The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group or heterocyclic group optionally having substituent(s); R is H, a hydrocarbon group or heterocyclic group optionally having substituent(s); A and R are optionally bonded to each other to form a ring optionally having substituent(s); Q1, Q2, Q3 and Q4 are each a hydrogen atom or a substituent; Q1 and Q2, and Q3 and Q4, are each optionally bonded to each other to form a ring optionally having substituent(s); X is H, an acyclic hydrocarbon group or saturated cyclic group optionally having substituent(s); Y1, Y2 and Y3 are each H, a hydrocarbon group or heterocyclic group optionally having substituent(s); X and Y1, and Y1 and Y2, are each optionally bonded to each other to form a ring optionally having substituent(s); and Z1, Z2 and Z3 are each H or a substituent, or a salt thereof.

公开(公告)号：US20240117346A1

公开(公告)日：2024-04-11

申请号：US17767663

申请日：2020-10-09

Applicant: National University Corporation Tokyo Medical and Dental University ,  Takeda Pharmaceutical Company Limited

Inventor： Takanori Yokota ,  Tetsuya Nagata ,  Hiroki Yamada ,  Hideki Furukawa ,  Takatoshi Yogo ,  Kenichi Miyata ,  Akio Uchida ,  Naoki Tomita

IPC: C12N15/113

CPC classification number: C12N15/113 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/341 ,  C12N2310/3515 ,  C12N2310/53 ,  C12N2320/51

Abstract: In an embodiment, an object of the present invention is to provide a double-stranded nucleic acid complex having a novel structure.
In an embodiment, the present invention relates to a nucleic acid complex comprising a first nucleic acid strand and a second nucleic acid strand, wherein said first nucleic acid strand: (1) is capable of hybridizing to at least a part of a target transcriptional product; (2) has an antisense effect on the target transcriptional product; and (3) is a gapmer comprising a central region, and a 5′ wing region and a 3′ wing region, said second nucleic acid strand comprises at least one sugar-unmodified central region (first exposed region) consisting of one sugar-unmodified ribonucleoside or two or three contiguous sugar-unmodified ribonucleosides linked by an internucleoside bond, which is or are complementary to a part of said first nucleic acid strand, and said first nucleic acid strand is annealed to said second nucleic acid strand.